VCEL - Vericel Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Vericel Corporation

64 Sidney Street
Cambridge, MA 02139
United States

Full Time Employees205

Key Executives

NameTitlePayExercisedYear Born
Mr. Dominick C. Colangelo Esq.Chief Exec. Officer, Pres, Treasurer and Director789.04kN/A1964
Mr. Gerard J. Michel MS, MBAChief Financial Officer and VP of Corp. Devel.507.74kN/A1963
Mr. Daniel R. OrlandoChief Operating Officer460.14kN/A1965
Ms. Jacquelyn Fahey SandellVP, Gen. Counsel and Corp. Sec.N/AN/AN/A
Ms. Heidi HassenSr. Director of HRN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Vericel Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.